Skip to main content

Table 3 Patients characteristics between two treatment groups

From: Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial

 

4R-CHOP+2R current study

6R-CHOP NCT 00854568159

P value

Characteristic

No. (%)

No. (%)

 

No. of patients

63

128

 

Age, year

   

Median (range)

47.9 (18–74)

49.3 (18–77)

 

≤60y

51 (81)

113 (88.3)

0.25

>60y

12 (19)

15 (11.7)

 

Gender

   

Male

36 (57.1)

72 (56.2)

0.97

Female

27 (42.9)

56 (43.8)

 

Ann Arbor Stage

   

I

27 (42.9)

63 (49.2)

0.50

II

36 (57.1)

65 (50.8)

 

ECOG PS

   

0

40 (63.5)

82 (64)

0.93

1

23 (36.5)

46 (36)

 

B symptoms

   

No

61 (96.8)

119 (93)

0.46

Yes

2 (3.2)

9 (7)

 

LDH level

   

Normal

60 (95.2)

120 (93.8)

0.93

Elevated

3 (4.8)

8 (6.3)

 

IPI score

   

0

51 (81)

106 (82.8)

0.13

1

10 (15.9)

22 (17.2)

 

2

2(3.2)

0 (0)

 
  1. Abbreviations: PS Performance Status, LDH Lactate Dehydrogenase, IPI International Prognostic Index